Zoetis (NYSE:ZTS) released its quarterly earnings results on Thursday. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06, Briefing.com reports. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.58 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The business’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.83 EPS. Zoetis updated its FY19 guidance to $3.57-3.62 EPS.

Shares of ZTS opened at $117.86 on Friday. Zoetis has a fifty-two week low of $78.90 and a fifty-two week high of $130.20. The firm’s 50 day moving average price is $125.46 and its 200 day moving average price is $116.48. The company has a market cap of $57.43 billion, a P/E ratio of 37.65, a PEG ratio of 2.98 and a beta of 0.88. The company has a quick ratio of 2.87, a current ratio of 4.17 and a debt-to-equity ratio of 2.74.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a yield of 0.56%. The ex-dividend date is Monday, October 21st. Zoetis’s payout ratio is currently 21.09%.

A number of equities research analysts have recently issued reports on ZTS shares. Credit Suisse Group set a $138.00 price target on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, October 11th. Barclays boosted their price target on shares of Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Craig Hallum boosted their price target on shares of Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. ValuEngine downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, SunTrust Banks boosted their price target on shares of Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research note on Tuesday, August 13th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $125.20.

In related news, EVP Kristin C. Peck sold 11,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $123.22, for a total transaction of $1,417,030.00. Following the sale, the executive vice president now directly owns 48,877 shares of the company’s stock, valued at approximately $6,022,623.94. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Roxanne Lagano sold 4,463 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $125.99, for a total transaction of $562,293.37. Following the sale, the executive vice president now directly owns 33,190 shares in the company, valued at $4,181,608.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,332 shares of company stock worth $4,258,182. 0.29% of the stock is owned by insiders.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: Systematic Risk and Investors

Earnings History for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.